R. Leos

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302

Shingo Matsumoto, Katarzyna A Rejniak, James B. Mitchell, 2015, Cancer & metabolism.

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

G. Weiss, J. Stephenson, Julie C Martin, 2012, Investigational New Drugs.

Chronic exposure to elevated norepinephrine suppresses insulin secretion in fetal sheep with placental insufficiency and intrauterine growth restriction.

R. Leos, Miranda J. Anderson, S. Limesand, 2010, American journal of physiology. Endocrinology and metabolism.

Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor.

A. Jimeno, R. Herbst, R. Kurzrock, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the “Steal” Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer

R. Gillies, A. Baker, G. Martinez, 2014, PloS one.

Radiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dodecafluoropentane Nano-Emulsion-Preliminary Findings.

A. Baker, E. Unger, R. Leos, 2015, Journal of biomedical nanotechnology.